Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055571 | 0.88 | NAMPT (0.49) | NAMPTHDAC1CHRM1HTR2AMCHR1 | |
| SCHEMBL3055626 | 0.87 | NAMPT (0.48) | NAMPTHDAC1CHRM1HTR2AMCHR1 | |
| SCHEMBL3051507 | 0.77 | ATR (0.50) | NAMPTHDAC1MCHR1 | |
| SCHEMBL3054387 | 0.76 | NAMPT (0.47) | NAMPTHDAC1CHRM1HTR2AMCHR1 | |
| SCHEMBL3050002 | 0.76 | NAMPT (0.47) | NAMPTHDAC1CHRM1HTR2AMCHR1 | |
| SCHEMBL3046675 | 0.76 | NAMPT (0.46) | NAMPTHDAC1CHRM1HTR2AMCHR1 | |
| SCHEMBL3046413 | 0.75 | NAMPT (0.46) | NAMPTHDAC1CHRM1HTR2AMCHR1 | |
| SCHEMBL3051247 | 0.75 | NAMPT (0.42) | NAMPTHDAC1CHRM1HTR2AMCHR1 | |
| SCHEMBL3058005 | 0.75 | NAMPT (0.54) | NAMPT | |
| SCHEMBL3050217 | 0.73 | HDAC1 (0.47) | NAMPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | claimed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | NAMPT 2/4885HDAC1 84/4885TRPV1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.